Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

AACR 2009: Genetic influences in response to EGFR for metastatic colorectal cancer

AACR 2009

18 - 22 Apr 2009

Published: 1 May 2009

Views: 17725

Rating:

Save

Frederica Di Nicolantonio - Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, University of Turin Medical School, Italy

Frederica Di Nicolantonio, Pharm.D., Ph.D., research fellow, Laboratory of Molecular Genetics, The Institute for Cancer Research and Treatment, University of Turin Medical School, speaking at AACR 2009, Denver: BRAF, PIK3CA and KRAS Mutations and Loss of PTEN Expression Impair Response to EGFR-Targeted Therapies in Metastatic Colorectal Cancer

Related Videos

Combination of cabozantinib and atezolizumab shows moderate activity in...

Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain

Combination of cabozantinib and atezolizumab shows moderate activity in treating metastatic adrenocortical carcinoma ( Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Somatic and germline heterogeneity across colorectal cancer patient...

Prof Jeffrey Weitzel - The University of Kansas Cancer Center, Kansas, USA

Somatic and germline heterogeneity across colorectal cancer patient characteristics: Implications for early cancer detection ( Prof Jeffrey Weitzel - The University of Kansas Cancer Center, Kansas, USA )

Whole exome sequencing reveals genomic landscape of appendiceal adenocarcinoma

Dr Michael White - MD Anderson Cancer Center, Houston, USA

Whole exome sequencing reveals genomic landscape of appendiceal adenocarcinoma ( Dr Michael White - MD Anderson Cancer Center, Houston, USA )

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

Latest treatments in oesophageal cancer

Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA

Latest treatments in oesophageal cancer ( Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA )

Choosing Wisely in implementing prevention, screening and early detection...

Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda

Choosing Wisely in implementing prevention, screening and early detection programs in Africa ( Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda )

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy...

Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )

More from ecancer